Research on Traditional Chinese Medicine for Treating UGT1A9 Gene Mutation-Related Diseases

Background and Potential

UGT1A9 gene mutations impair UDP-glucuronosyltransferase activity, leading to bilirubin metabolism disorders like Gilbert syndrome or drug metabolism abnormalities. In TCM, such disorders are linked to “damp-heat accumulation” or “liver-spleen disharmony.” Herbs like Capillaris and Gardenia (heat-clearing, damp-resolving) and Bupleurum and Curcuma (liver-regulating) may enhance liver enzyme activity and bilirubin excretion. Compound formulas like Yinchenhao Decoction and Xiaochaihu Decoction, used for jaundice and liver disorders, may benefit UGT1A9 mutation-related conditions.

Pharmacological studies suggest geniposide (from Gardenia) has antioxidant and hepatoprotective effects, potentially upregulating UGT enzyme activity to improve bilirubin metabolism. Yinchenhao Decoction may regulate liver P450 enzymes, possibly addressing UGT1A9 mutation-related metabolic defects. Thus, TCM for UGT1A9 mutation-related diseases warrants investigation.

Research Methods

1. Herb Screening and Formula Design

• Single Herb Screening: Select heat-clearing (Capillaris, Gardenia), liver-regulating (Bupleurum, Curcuma), and blood-activating (Salvia) herbs. Analyze active components (e.g., geniposide, saikosaponin) and their effects on UGT1A9-related metabolic pathways.
• Compound Formula Design: Modify Yinchenhao Decoction by adding Bupleurum and Curcuma to address “damp-heat and liver stagnation.”
• Pharmacological Basis: Use LC-MS to identify key active components in formulas, clarifying their pharmacological basis.

2. Cell Model Construction

• Cell Line Selection: Use HEK293 cells for gene editing or HepG2 cells (human hepatoma cells) to model liver metabolism.
• Precise Gene Editing:
  1. Design gRNA targeting UGT1A9 gene (e.g., c.-3279T>G mutation).
  2. Construct CRISPR/Cas9 plasmids and transfect into HEK293 or HepG2 cells.
  3. Screen for stable UGT1A9 mutant cell lines via single-cell cloning.
• Mutation Validation: Verify mutations with Sanger sequencing; assess UGT1A9 expression with qPCR and Western blot; evaluate enzyme activity via glucuronidation assays.

3. TCM Intervention Experiments

• In Vitro Experiments:
  1. Divide UGT1A9 mutant cells into control, single herb (e.g., geniposide, saikosaponin), and compound formula groups (e.g., modified Yinchenhao Decoction).
  2. Measure bilirubin metabolism levels (HPLC), cell viability, and enzyme activity post-intervention.
  3. Analyze related pathways (e.g., liver metabolism enzymes) using qPCR and Western blot.
• Dose Optimization: Determine optimal intervention concentrations and assess cytotoxicity.

4. Validation Methods

• Functional Validation: Assess bilirubin metabolism improvement via HPLC; measure UGT enzyme activity changes.
• Molecular Mechanism Validation: Examine UGT1A9 and related gene expression to identify TCM’s molecular targets.
• In Vivo Validation: Construct UGT1A9 mutant mouse models, administer TCM, and evaluate bilirubin levels, liver function, and enzyme expression.

Expected Outcomes and Significance

TCM may enhance bilirubin metabolism and liver function in UGT1A9 mutant cells through multi-target mechanisms. These findings could provide new TCM-based strategies for treating Gilbert syndrome and related disorders, advancing the integration of TCM with precision medicine.